Trials / Unknown
UnknownNCT04946266
Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 260 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An exploratory analysis of the expression of MFI2-AS1 will be performed at the plasma level with the objective of comparing this expression with tumor tissue. The objective would be to be able to use long non-coding RNA as a biomarker for diagnosis before tissue analysis and for patient follow-up. In addition, correlations will be made between tumor expression of MFI2-AS1 and genetic and immune alterations in tumors in order to better clarify the link between the expression of this long non-coding RNA and the characteristics of the tumor and of the tumor. tumor microenvironment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Surgical intervention | Surgical intervention with collection of tissue material |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2021-12-01
- Completion
- 2024-12-01
- First posted
- 2021-06-30
- Last updated
- 2022-01-05
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04946266. Inclusion in this directory is not an endorsement.